Delivered dose and fine particle dose of aclidinium bromide 200 µg via the Genuair® inhaler are independent of flow rate within the working range of the device

K. Block, S. Folger, B. Fyrnys, S. Kurtz (Bad Homburg, Germany)

Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Session: Drug delivery and pharmacokinetics I
Session type: E-Communication Session
Number: 2037
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Block, S. Folger, B. Fyrnys, S. Kurtz (Bad Homburg, Germany). Delivered dose and fine particle dose of aclidinium bromide 200 µg via the Genuair® inhaler are independent of flow rate within the working range of the device. Eur Respir J 2010; 36: Suppl. 54, 2037

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Similar delivery of ipratropium bromide is possible at approximately one-half dose via a breath-actuated nebulizer compared with a continuous nebulizer
Source: Eur Respir J 2005; 26: Suppl. 49, 306s
Year: 2005

Different inhalation volumes do not impact on the aerodynamics of aclidinium bromide delivered using the Genuair® inhaler
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010


Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Flutide™ Diskus™ less consistent than Pulmicort® Turbuhaler® with respect to in vitro fine particle dose proportionality
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation
Source: Eur Respir J 2001; 18: Suppl. 33, 102s
Year: 2001

Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

In vitro comparison of aerosol characteristics of HFA ipratropium bromide pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Tiotropium dose emission is influenced by the inhalation flow and the recommended two inhalations for each dose
Source: Eur Respir J 2005; 26: Suppl. 49, 125s
Year: 2005

Sub-microgram dose formulations for dose ranging studies with long acting bronchodilators and their fixed dose combination using metered dose inhalers (MDIs)
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013

Improvement in the drug delivery of salmeterol/fluticasone via a novel breath actuatedpressurized metered dose inhaler with a dose counter
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 69s
Year: 2001

Dose emission from a formoterol aerolizer is dependent on inhalation flow and volume
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009


Improved delivery of fenoterol plus ipratropium bromide using Respimat(R) compared with a conventional metered dose inhaler
Source: Eur Respir J 2001; 17: 225-232
Year: 2001



Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Assessment of the suitability of filters for use in clinical studies with an HFA fluticasone propionate pressurized metered dose inhaler (pMDI) and a valved holding chamber (VHC)
Source: Annual Congress 2011 - Lung function today and tomorrow II
Year: 2011

In vitro dosage emission for different flow rates from a combination of eformoterol and budesonide in a dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 134s
Year: 2001